- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02371694
What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM? (REQINSOIL)
What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With Type 1 Diabetes Mellitus?
Background: Based on international evidence, current management of people with T1DM on intensive insulin therapy (IIT) use algorithms based on the meal carbohydrate content (MCC) to calculate the prandial insulin dose. Typically, these calculations do not take into account the protein or fat content of the meal. There is a lack of clinical advice for optimal management of high protein/fat meals due to a paucity of evidence regarding the impact of protein/fat on glycaemic control.
Objective: To determine the mean glucose excursion from fasting (measured by continuous glucose monitoring, CGMS) at each 30 minute interval over the 8 hour postprandial period for each test condition. Protein effects will be looked at in a separate parallel study in Australia.
Hypothesis: The fat content of a meal will cause a dose-response change in the postprandial glucose concentration in children with T1DM.
Research Design and Methods: Randomised cross-over study involving thirty patients. Inclusion criteria: T1DM >1 year, aged 8-18 years, with HbA1c <8% and BMI <91st centile, on intensive insulin therapy. Participants will be given a test meal on 6 consecutive nights in random order; 4 test meals varying in fat content, and one 20g carbohydrate test meal with zero fat given as control meal. A CGMS will be used to assess glucose responses at 5 minute intervals for 8 hours after test meal consumption. The relationship between the fat loads in the test meals and the mean change in postprandial glucose concentration will be analysed and described.
Conclusions: This study will determine whether fat causes dose dependent response in glucose concentrations leading to refining the guidelines and possible adjustment of insulin doses for the fat content of a meal.
Study Overview
Detailed Description
Aims of the project To determine the postprandial glucose dose-response curves response to varying fat amounts by studying various parameters (glycaemic excursion, rate of glucose level increase, area under the curve, percent time in target glucose range, maximal glucose excursion, time to maximal glucose excursion and time until the glucose level returns to fasting concentration) provided by continuous glucose monitoring over a 6 day study period with a view to provide data to calculate an accurate insulin dosing schedule to account for varying dietary fat ingestion.
Objective 1 To define the impact of varying quantities (dose) of fat on the post-prandial glucose concentrations i.e. determine the relationship between the fat load in the test meals and the mean change in postprandial glucose concentrations.
Objective 2 To compare the impact of the varying fat quantities in the test meals each with a control carbohydrate snack (20g) without extra insulin.
Protocol Participants will be contacted daily for one week prior to the study to review their overnight and fasting glucose concentrations and if necessary, adjust their insulin doses. The study will be carried out during a week long period for each patient. Participants will be given test meals over 6 consecutive days in random order, with 5 test meals varying in lipid content and one carbohydrate (20g) test meal as comparator. A continuous glucose monitoring system (CGMS) will be inserted on the day of the first test meal and will be removed at the completion of the sixth night.
To define the impact of lipid on the post-prandial glucose concentration, participants will consume a standardised meal at 18:00hours and receive a standard insulin bolus by injection or pump (using standard wave bolus if on insulin pump) based on the meal carbohydrate content. At 22:00 hours the participants will consume a lipid test meal dose (varying fat content of 2.5, 12.5, 25, 37.5, 50g) or carbohydrate snack 20g. The calculations of the fat doses have been based on the Pankowska algorithm [3] which recommends additional insulin for every 100 kcal fat or protein. There will be randomised order of test meals.
Test meals will be formulated to be palatable, consumed within 5 minutes and to contain negligible carbohydrate, protein and fibre. A dietician will design the test meals in conjunction with the co-investigator in detail to ensure ease of formulation and practical administration.
The lipid dose in test meals will be tested for acceptability and palatability to ensure adherence to protocol. The order of the test meal types/carbohydrate snacks will be random (computer generated randomisation). The comparator 20g carbohydrate snack has been included to assess the participant's typical glucose response to 20g of carbohydrate. No insulin will be given for the lipid or carbohydrate snacks. Participants will fast until breakfast.
- Outcomes Glucose concentrations will be measured at the start of the test meal and at 5 minute intervals over the 8 hour postprandial period. Therefore, the data will consist of repeated measurements on the same individual within test meal loads as well as the same individuals across test meal loads.
The primary outcome of interest will be the Area Under the Curve (AUC) of glucose concentrations during the post prandial 8 hours. Linear regressions, within a generalised linear mixed model framework, will be used to test for a dose response in AUCs with increasing size of fat means.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland, T12 DC4A
- Cork University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with T1DM for more than 1 year
- HbA1c less than 8%
- BMI less than 91st centile
- on intensive insulin therapy
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Fat Test drink (50g)
This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
|
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume. All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour. |
|
EXPERIMENTAL: Fat Test drink (38g)
This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
|
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume. All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour. |
|
EXPERIMENTAL: Fat Test drink (25g)
This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
|
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume. All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour. |
|
EXPERIMENTAL: Fat Test drink (13g)
This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
|
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume. All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour. |
|
PLACEBO_COMPARATOR: Fat Test drink (3g)
This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
|
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume. All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour. |
|
ACTIVE_COMPARATOR: Carbohydrate Test drink
This drink contains 20g of glucose from de-gassed lucozade energy.
|
The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume. All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycaemic excursion
Time Frame: During the 8 hours post drink
|
The mean glucose excursion from fasting (measured by CGMS) at each 30 minute interval over the 8 hour postprandial period for each test condition
|
During the 8 hours post drink
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximal glucose excursion
Time Frame: During the 24h post drink
|
Maximal change in glucose concentration (mMol)
|
During the 24h post drink
|
|
Time to maximal glucose excursion
Time Frame: During the 8 hours post drink
|
Duration to reach maximal change in glucose concentration (minutes)
|
During the 8 hours post drink
|
|
Time until the glucose level returns to baseline
Time Frame: During the 8 hours post drink
|
Duration to reach basal glucose concentration (minutes)
|
During the 8 hours post drink
|
|
Percent time in target glucose range
Time Frame: During the 24h post drink
|
Duration spent in target glucose concentration (Minutes)
|
During the 24h post drink
|
|
Number of hypoglycaemic events in the 24h post-test meal
Time Frame: During the 24 hours post drink
|
Number of hypoglycaemic events
|
During the 24 hours post drink
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Susan O'Connell, MD, Cork University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CorkUH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...Not yet recruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes Mellitus
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Abdullah KarsNot yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)Turkey (Türkiye)
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Al-Zaytoonah University of JordanActive, not recruitingType 1 Diabetes | Type 1 Diabetes MellitusEgypt
Clinical Trials on Test drink
-
Hacettepe UniversityAnkara UniversityCompletedBody Weight | Appetite | Dietary IntakeTurkey
-
Société des Produits Nestlé (SPN)Completed
-
Mednax Center for Research, Education, Quality...Banner University Medical CenterTerminated
-
University of FloridaCompletedDrug Induced Hyperglycemia | Secondary HyperlipidemiaUnited States
-
Wageningen UniversityMaastricht University Medical Center; Top Institute Food and NutritionCompleted
-
Mayo ClinicCompletedCardiovascular System | Hemodynamics | Energy DrinksUnited States
-
Mondelēz International, Inc.Reading Scientific Services Ltd.CompletedGlycaemic Index | Glycaemic ResponseUnited Kingdom
-
University of LausanneCompleted
-
Virginia Polytechnic Institute and State UniversityCompletedCardiovascular Risk FactorUnited States